Universal vaccine against respiratory syncytial virus A and B subtypes

PLoS ONE

Volumn 12, Issue 4, 2017, Pages

  Lee, Jeong Yoon ^a   Chang, Jun ^a  

^a Ewha Womans University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN; GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; PEPTIDE VACCINE; RECOMBINANT GCFAB FUSION PROTEIN VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL COUNT; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN RESPIRATORY SYNCYTIAL VIRUS; HUMAN RESPIRATORY SYNCYTIAL VIRUS A; HUMAN RESPIRATORY SYNCYTIAL VIRUS B; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOPATHOLOGY; LUNG LAVAGE; MOUSE; NONHUMAN; PROTECTION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VACCINE IMMUNOGENICITY; VIRUS LOAD; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CLASSIFICATION; HUMAN; IMMUNOLOGY; LUNG; VIROLOGY;

ANIMALS; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; LUNG; MICE; MICE, INBRED BALB C; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN;

EID: 85017107268     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0175384     Document Type: Article

References (53)

1. Welliver RC. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J Pediatr-Us. 2003; 143(5):S112-S7.
2. Johnson TR, Graham BS. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection. Pediatric Infectious Disease Journal. 2004; 23(1):S46-S56.
3. Walsh EE, Hall CB, Schlesinger JJ, Brandriss MW, Hildreth S, Paradiso P. Comparison of antigenic sites of subtype-specific respiratory syncytial virus attachment proteins. J Gen Virol. 1989; 70 (Pt 11):2953-61.
4. Mufson MA, Orvell C, Rafnar B, Norrby E. Two distinct subtypes of human respiratory syncytial virus. J Gen Virol. 1985; 66 (Pt 10):2111-24.
5. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986; 140(6):543-6. PMID: 3706232
6. Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis. 1991; 163(4):693-8. PMID: 2010624
7. Falsey AR. Respiratory syncytial virus infection in elderly and high-risk adults. Exp Lung Res. 2005; 31 Suppl 1:77.
8. Connors M, Giese NA, Kulkarni AB, Firestone CY, Morse HC 3rd, Murphy BR. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSVimmunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol. 1994; 68 (8):5321-5. Epub 1994/08/01. PMID: 8035532
9. Kim HW, Leikin SL, Arrobio J, Brandt CD, Chanock RM, Parrott RH. Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection. Pediatr Res. 1976; 10(1):75-8. https://doi.org/10.1203/00006450-197601000-00015 PMID: 1246465
10. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969; 89(4):422-34. Epub 1969/04/01. PMID: 4305198
11. Piedra PA, Faden HS, Camussi G, Wong DT, Ogra PL. Mechanism of lung injury in cotton rats immunized with formalin-inactivated respiratory syncytial virus. Vaccine. 1989; 7(1):34-8. PMID: 2655343
12. Piedra PA, Wyde PR, Castleman WL, Ambrose MW, Jewell AM, Speelman DJ, et al. Enhanced pulmonary pathology associated with the use of formalin-inactivated respiratory syncytial virus vaccine in cotton rats is not a unique viral phenomenon. Vaccine. 1993; 11(14):1415-23. PMID: 7508665
13. Srikiatkhachorn A, Braciale TJ. Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J Exp Med. 1997; 186(3):421-32. Epub 1997/08/04. PMID: 9236194
14. Hancock GE, Speelman DJ, Heers K, Bortell E, Smith J, Cosco C. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J Virol. 1996; 70(11):7783-91. PMID: 8892899
15. Openshaw PJ, Clarke SL, Record FM. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int Immunol. 1992; 4(4):493-500. Epub 1992/04/01. PMID: 1591217
16. Murata Y, Lightfoote PM, Biear JN, Falsey AR, Walsh EE. Humoral response to the central unglycosylated region of the respiratory syncytial virus attachment protein. Vaccine. 2010; 28(38):6242-6. https:// doi.org/10.1016/j.vaccine.2010.07.011 PMID: 20655403
17. Plotnicky-Gilquin H, Goetsch L, Huss T, Champion T, Beck A, Haeuw JF, et al. Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein. J Virol. 1999; 73(7):5637-45. PMID: 10364313
18. Tebbey PW, Hagen M, Hancock GE. Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus. Journal of Experimental Medicine. 1998; 188(10):1967-72. PMID: 9815273
19. Melero JA, Garcia-Barreno B, Martinez I, Pringle CR, Cane PA. Antigenic structure, evolution and immunobiology of human respiratory syncytial virus attachment (G) protein. J Gen Virol. 1997; 78 (Pt 10):2411-8.
20. Choi Y, Mason CS, Jones LP, Crabtree J, Jorquera PA, Tripp RA. Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains. Viral Immunol. 2012; 25(3):193-203. Epub 2012/05/04. https:// doi.org/10.1089/vim.2011.0094 PMID: 22551066
21. Harcourt JL, Karron RA, Tripp RA. Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis. J Infect Dis. 2004; 190(11):1936-40. https://doi.org/10.1086/425516 PMID: 15529257
22. Zhang W, Choi Y, Haynes LM, Harcourt JL, Anderson LJ, Jones LP, et al. Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice. J Virol. 2010; 84(2):1148-57. Epub 2009/10/30. https:// doi.org/10.1128/JVI.01755-09 PMID: 19864390
23. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol. 2006; 6(2):148-58. https://doi.org/10.1038/nri1777 PMID: 16491139
24. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med. 2005; 11(4 Suppl):S45-53. https://doi.org/10.1038/nm1213 PMID: 15812489
25. Cuburu N, Kweon MN, Song JH, Hervouet C, Luci C, Sun JB, et al. Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine. 2007; 25(51):8598-610. https://doi.org/10.1016/j.vaccine.2007.09.073 PMID: 17996991
26. Armstrong ME, Lavelle EC, Loscher CE, Lynch MA, Mills KHG. Proinflammatory responses in the murine brain after intranasal delivery of cholera toxin: Implications for the use of AB toxins as adjuvants in intranasal vaccines. Journal of Infectious Diseases. 2005; 192(9):1628-33. https://doi.org/10.1086/ 491739 PMID: 16206078
27. Jang JE, Lee JB, Kim KH, Park SM, Shim BS, Cheon IS, et al. Evaluation of Protective Efficacy of Respiratory Syncytial Virus Vaccine against A and B Subgroup Human Isolates in Korea. Plos One. 2011; 6(9).
28. Kim S, Joo DH, Lee JB, Shim BS, Cheon IS, Jang JE, et al. Dual Role of Respiratory Syncytial Virus Glycoprotein Fragment as a Mucosal Immunogen and Chemotactic Adjuvant. Plos One. 2012; 7(2).
29. Cheon IS, Shim BS, Park SM, Choi Y, Jang JE, Jung DI, et al. Development of Safe and Effective RSV Vaccine by Modified CD4 Epitope in G Protein Core Fragment (Gcf). Plos One. 2014; 9(4).
30. Brandtzaeg P. Role of secretory antibodies in the defence against infections. Int J Med Microbiol. 2003; 293(1):3-15. https://doi.org/10.1078/1438-4221-00241 PMID: 12755363
31. Power UF, Plotnicky-Gilquin H, Goetsch L, Champion T, Beck A, Haeuw JF, et al. Identification and characterisation of multiple linear B cell protectopes in the respiratory syncytial virus G protein. Vaccine. 2001; 19(17-19):2345-51. PMID: 11257359
32. Trudel M, Nadon F, Seguin C, Binz H. Protection of BALB/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G glycoprotein. Virology. 1991; 185 (2):749-57. PMID: 1720589
33. Murata Y, Catherman SC. Antibody response to the central unglycosylated region of the respiratory syncytial virus attachment protein in mice. Vaccine. 2012; 30(36):5382-8. https://doi.org/10.1016/j. vaccine.2012.06.016 PMID: 22728222
34. Cane PA, Thomas HM, Simpson AF, Evans JE, Hart CA, Pringle CR. Analysis of the human serological immune response to a variable region of the attachment (G) protein of respiratory syncytial virus during primary infection. J Med Virol. 1996; 48(3):253-61. https://doi.org/10.1002/(SICI)1096-9071(199603) 48:3253::AID-JMV73.0.CO;2-7 PMID: 8801286
35. Varga SM, Wissinger EL, Braciale TJ. The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2CD4(+) T cell responses. Journal of Immunology. 2000; 165(11):6487-95.
36. Srikiatkhachorn A, Chang W, Braciale TJ. Induction of Th-1 and Th-2 responses by respiratory syncytial virus attachment glycoprotein is epitope and major histocompatibility complex independent. Journal of Virology. 1999; 73(8):6590-7. PMID: 10400756
37. Varga SM, Wang XT, Welsh RM, Braciale TJ. Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells. Immunity. 2001; 15(4):637-46. PMID: 11672545
38. Durbin JE, Johnson TR, Durbin RK, Mertz SE, Morotti RA, Peebles RS, et al. The role of IFN in respiratory syncytial virus pathogenesis. Journal of Immunology. 2002; 168(6):2944-52.
39. Plotnicky-Gilquin H, Robert A, Chevalet L, Haeuw JF, Beck A, Bonnefoy JY, et al. CD4(+) T-cell-mediated antiviral protection of the upper respiratory tract in BALB/c mice following parenteral immunization with a recombinant respiratory syncytial virus G protein fragment. Journal of Virology. 2000; 74 (8):3455-63. PMID: 10729118
40. Graham BS, Johnson TR, Peebles RS. Immune-mediated disease pathogenesis in respiratory syncytial virus infection. Immunopharmacology. 2000; 48(3):237-47. PMID: 10960663
41. Alwan WH, Kozlowska WJ, Openshaw PJ. Distinct types of lung disease caused by functional subsets of antiviral T cells. J Exp Med. 1994; 179(1):81-9. PMID: 8270885
42. Tripp RA, Moore D, Jones L, Sullender W, Winter J, Anderson LJ. Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice. J Virol. 1999; 73(9):7099-107. PMID: 10438795
43. Castilow EM, Legge KL, Varga SM. Cutting Edge: Eosinophils Do Not Contribute to Respiratory Syncytial Virus Vaccine-Enhanced Disease. J Immunol. 2008; 181(10):6692-6. PMID: 18981084
44. Mangodt TC, Van Herck MA, Nullens S, Ramet J, De Dooy JJ, Jorens PG, et al. The role of Th17 and Treg responses in the pathogenesis of RSV infection. Pediatric Research. 2015; 78(5):483-91. https:// doi.org/10.1038/pr.2015.143 PMID: 26267154
45. Bystrom J, Al-Adhoubi N, Al-Bogami M, Jawad AS, Mageed RA. Th17 Lymphocytes in Respiratory Syncytial Virus Infection. Viruses-Basel. 2013; 5(3):777-91.
46. Mukherjee S, Lindell DM, Berlin AA, Morris SB, Shanley TP, Hershenson MB, et al. IL-17-Induced Pulmonary Pathogenesis during Respiratory Viral Infection and Exacerbation of Allergic Disease. American Journal of Pathology. 2011; 179(1):248-58. https://doi.org/10.1016/j.ajpath.2011.03.003 PMID: 21703407
47. Lee JB, Jang JE, Song MK, Chang J. Intranasal delivery of cholera toxin induces th17-dominated T-cell response to bystander antigens. PLoS One. 2009; 4(4):e5190. https://doi.org/10.1371/journal.pone. 0005190 PMID: 19360100
48. Harcourt JL, Karron RA, Tripp RA. Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis. Journal of Infectious Diseases. 2004; 190(11):1936-40. PMID: 15529257
49. Haynes LM, Caidi H, Radu GU, Miao C, Harcourt JL, Tripp RA, et al. Therapeutic Monoclonal Antibody Treatment Targeting Respiratory Syncytial Virus (RSV) G Protein Mediates Viral Clearance and Reduces the Pathogenesis of RSV Infection in BALB/c Mice. Journal of Infectious Diseases. 2009; 200 (3):439-47. https://doi.org/10.1086/600108 PMID: 19545210
50. Haynes LM, Jones LP, Barskey A, Anderson LJ, Tripp RA. Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P. Journal of Virology. 2003; 77 (18):9831-44. https://doi.org/10.1128/JVI.77.18.9831-9844.2003 PMID: 12941892
51. Zhang WL, Choi YJ, Haynes LM, Harcourt JL, Anderson LJ, Jones LP, et al. Vaccination To Induce Antibodies Blocking the CX3C-CX3CR1 Interaction of Respiratory Syncytial Virus G Protein Reduces Pulmonary Inflammation and Virus Replication in Mice. Journal of Virology. 2010; 84(2):1148-57. https:// doi.org/10.1128/JVI.01755-09 PMID: 19864390
52. Jafri HS, Wu XH, Makari D, Henrickson KJ. Distribution of Respiratory Syncytial Virus Subtypes A and B Among Infants Presenting to the Emergency Department With Lower Respiratory Tract Infection or Apnea. Pediatric Infectious Disease Journal. 2013; 32(4):335-40. https://doi.org/10.1097/INF. 0b013e318282603a PMID: 23337904
53. Papadopoulos NG, Gourgiotis D, Javadyan A, Bossios A, Kallergi K, Psarras S, et al. Does respiratory syncytial virus subtype influences the severity of acute bronchiolitis in hospitalized infants? Resp Med. 2004; 98(9):879-82.